I-Mab to Start US Phase I Trial of Immunotherapy for Alzheimer's

Shanghai 's I-Mab has been cleared to start a US Phase I trial of its novel immunotherapy for Alzheimer's. Protollin is composed of outer membrane bacteria proteins complexed with lipopolysaccharides that is delivered nasally to cross the brain-blood barrier. It is aimed at stimulating an immune response against the build-up of beta amyloid protein plaques and subsequent tau tangles. I-Mab will develop protollin ex-China; Nhwa owns China rights. The two China biopharmas in-licensed global rights to the candidate from Boston 's Brigham and Women's Hospital and Inspirevax, a Montreal biotech. More details.... Stock Symbol: (NSDQ: IMAB) Share this with colleagues: // //